for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc (ADR)

AZN

Latest Trade

55.72USD

Change

-0.24(-0.42%)

Volume

1,979,948

Today's Range

55.52

 - 

56.24

52 Week Range

36.15

 - 

64.94

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
55.95
Open
56.09
Volume
1,979,948
3M AVG Volume
151.36
Today's High
56.24
Today's Low
55.52
52 Week High
64.94
52 Week Low
36.15
Shares Out (MIL)
1,312.27
Market Cap (MIL)
145,675.50
Forward P/E
28.40
Dividend (Yield %)
3.31

Next Event

Dividend For AZN.L - 69.6000 GBX

Latest Developments

More

Redx Pharma Signs Out Licensing Agreement With AstraZeneca

Astrazeneca Plc Prices $3 Bln Bond Issue

Wockhardt Intends To Supply 30 Mln Fill-&-Finish COVID-19 Vaccine Doses To AstraZeneca

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc (ADR)

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

CB2 0AA

United Kingdom

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Fiona Cicconi

Executive Vice President - Human Resources

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.5K

2018

22.1K

2019

24.4K

2020(E)

26.4K
EPS (USD)

2017

2.140

2018

1.730

2019

1.750

2020(E)

1.960
Price To Earnings (TTM)
68.39
Price To Sales (TTM)
5.67
Price To Book (MRQ)
12.00
Price To Cash Flow (TTM)
24.96
Total Debt To Equity (MRQ)
161.37
LT Debt To Equity (MRQ)
127.60
Return on Investment (TTM)
4.83
Return on Equity (TTM)
3.36

Latest News

Latest News

AstraZeneca in first COVID-19 vaccine deal with Chinese company

Shenzhen Kangtai Biological Products <300601.SZ> will produce AstraZeneca Plc's <AZN.L> potential COVID-19 vaccine in mainland China, the British drugmaker said on Thursday, its first deal to supply one of the world's most populous countries.

AstraZeneca in deal with Kangtai Bio to supply potential COVID-19 vaccine in China

AstraZeneca PLC has signed an exclusive framework agreement with China's Shenzhen Kangtai Biological Products to supply its COVID-19 vaccine candidate in mainland China, the British pharmaceutical giant said on Thursday.

India's Wockhardt strikes deal to supply COVID-19 vaccines to UK

Indian drugmaker Wockhardt Ltd will supply millions of doses of multiple COVID-19 vaccines, including that being developed by AstraZeneca and Oxford University, under a deal with the UK government announced on Monday.

AstraZeneca to be exempt from coronavirus vaccine liability claims in most countries

AstraZeneca has been granted protection from future product liability claims related to its COVID-19 vaccine hopeful by most of the countries with which it has struck supply agreements, a senior executive told Reuters.

'So far, so good' on leading COVID vaccine, says AstraZeneca

Britain's AstraZeneca <AZN.L> said on Thursday that good data was coming in so far on its vaccine for COVID-19, already in large-scale human trials and widely seen as the front-runner in the race for a shot against the novel coronavirus.

AstraZeneca to be exempted from coronavirus vaccine liability claims in most countries

AstraZeneca has been granted protection from future product liability claims related to its COVID-19 vaccine hopeful by most of the countries it has so far struck supply agreements with, a senior executive told Reuters.

BRIEF-AstraZeneca Not Hit By U.S.-China Tensions Over Pandemic - Media Call

* ASTRAZENECA SAYS NEW LAUNCHES FOR CALQUENCE AND ENHERTU ARE SHOWING GOOD PROGRESS - MEDIA CALL

Lloyds Bank loss hits FTSE 100, AstraZeneca gains

Gloomy quarterly results from Lloyds Bank and a clutch of other companies led the FTSE 100 lower on Thursday, while AstraZeneca rose after topping analysts' expectations on the back of strong drug sales during coronavirus-driven lockdowns.

AstraZeneca tops forecasts on strong drug sales, outlook unchanged

Drugmaker AstraZeneca topped second-quarter sales and profit expectations on Thursday and stood by its 2020 forecasts, helped by strong sales in lockdowns of a diverse line-up, which now includes a potential coronavirus vaccine.

AstraZeneca diabetes drug shows promise in severe kidney condition

AstraZeneca's diabetes treatment has shown promise in a late-stage trial to help to slow chronic kidney disease, putting it on track for possible expanded approvals ahead of rival drugs.

AstraZeneca bets up to $6 billion on new Daiichi cancer drug

AstraZeneca <AZN.L> will pay up to $6 billion to Japan's Daiichi Sankyo <4568.T> under the drugmakers' second multi-billion dollar oncology collaboration to develop and market a new type of targeted cancer treatment.

Emergent signs $174 million deal to make AstraZeneca's potential COVID-19 vaccine

Emergent BioSolutions Inc said on Monday it signed a $174 million agreement with AstraZeneca to develop and manufacture the British drugmaker's COVID-19 vaccine candidate.

Emergent signs $174 mln deal to make AstraZeneca's potential COVID-19 vaccine

Emergent BioSolutions Inc said on Monday it signed a $174 million agreement with AstraZeneca to develop and manufacture the British drugmaker's COVID-19 vaccine candidate.

AstraZeneca to pay up to $6 bln in new cancer drug deal with Daiichi

British drugmaker AstraZeneca could pay up to $6 billion to Japan's Daiichi Sankyo as part of a new collaboration to develop and market a type of potential cancer treatment for multiple tumour types.

AstraZeneca's lung disease treatment gets FDA nod

The U.S. Food and Drug Administration approved AstraZeneca's drug to treat patients with a form of lung disease, the British drugmaker said on Friday.

AstraZeneca's lung disease treatment gets FDA nod

The U.S. Food and Drug Administration approved AstraZeneca's drug to treat patients with a form of lung disease, the drugmaker said on Friday.

South Korea's SK Bioscience in deal with AstraZeneca on vaccine

South Korea's SK Bioscience has agreed to manufacture AstraZeneca's experimental COVID-19 vaccine to help the British company build global supplies of the vaccine that has shown promise against the new coronavirus, it said on Tuesday.

S.Korea's SK Bioscience in deal with AstraZeneca on vaccine

SK Bioscience has signed a letter of intent with Britain's AstraZeneca for global production of its experimental COVID-19 vaccine, the South Korean company said on Tuesday.

Factbox: AstraZeneca's potential coronavirus vaccine

AstraZeneca's experimental COVID-19 vaccine was safe and produced an immune response in early-stage clinical trials in healthy volunteers, data showed on Monday.

Equity markets rebound on EU fund optimism; gold edges higher

Global equity markets rebounded on Monday on optimism the European Union would approve a recovery fund to help revive regional economies hit by the coronavirus, but worries about the pandemic's economic and human toll pushed gold prices higher.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up